Admiral quadruples its profits thanks to biological treatments

BarcelonaAlmirante continues to deepen its specialization in dermatology. This is reflected in 2025, as the company quadrupled its profits to €46.2 million thanks to its portfolio of biological treatments, compared to €10.1 million in 2024. Group sales exceeded €1 billion, specifically €1.108 billion, representing a 12.4% increase over the previous year. Total revenue was €1.114 billion, up 12.5%. Operating profit (EBITDA) reached €232.9 million, a 20.9% year-on-year increase, and the gross margin was 64.4%. The key driver of these results was dermatology sales in Europe, which increased by 25.6% to €608 million, the company reported in a statement on Monday.

The company, led by Carles Gallardo, highlights that atopic dermatitis (AD) and psoriasis (PSO), key areas within medical dermatology—the major specialty Almirall has focused on—represent "a significant opportunity" for the group. The company notes the increase in diagnosed patients and their potential to benefit from advanced treatment options.

They also highlight the performance of Lebrikizumab, for the treatment of moderate to severe atopic dermatitis, with sales of €110.8 million; and Tildrakizumab, for the treatment of moderate to severe psoriasis, with sales of €234.4 million.

Biologic treatments are the cornerstone of the 2025 results. Sales of Ilumetrio, for the treatment of plaque psoriasis, have grown by 12.3% year-on-year, reaching €234.4 million. Sales of Ebglyss, for moderate to severe atopic dermatitis, have tripled to 110.8 million. Topical alternatives for treating dermatological problems have also seen positive growth. The company continued its research and development (R&D) efforts in 2025 to address another drug for alopecia areata (AA) and the approval of Jublia in Germany and Seysara in China. For this year, Almirall anticipates net sales growth of between 9% and 12% and operating profit (EBITDA) of between €270 million and €290 million.